<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05792865</url>
  </required_header>
  <id_info>
    <org_study_id>CYH-PHARM1</org_study_id>
    <nct_id>NCT05792865</nct_id>
  </id_info>
  <brief_title>A Registry Study of Patients Hospitalized With Confirmed COVID-19</brief_title>
  <official_title>A Registry Study of Patients Hospitalized With Confirmed COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The design of this registered study aims to evaluate the efficacy and safety of Paxlovid in&#xD;
      the treatment of hospitalized COVID-19 patients, and to explore factors related to the&#xD;
      efficacy and safety of Paxlovid.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2023</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>Disease progression rates</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The proportion of patients who experienced any of the following events within 28 days after being diagnosed with COVID-19, including all-cause mortality, requiring invasive mechanical ventilation, or being admitted to the intensive care unit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause deaths rates</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The proportion of patients who experienced all-cause mortality within 28 days after being diagnosed with COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rehospitalization event rates</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The proportion of patients who experienced a rehospitalization event within 28 days after being diagnosed with COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 repositive event rates</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The proportion of patients who experienced a COVID-19 repositive event within 28 days after being diagnosed with COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse drug reaction event</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The proportion of patients who experienced any adverse drug reaction events within 28 days after being diagnosed with COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thromboembolic event rates</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The proportion of patients who experienced thromboembolic events, including deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, within 28 days after being diagnosed with COVID-19.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">488</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Paxlovid（Within 5 days after the diagnosis of COVID-19）</arm_group_label>
    <description>According to the patient's medical records, the time from the diagnosis of COVID-19 to the prescription of PAXLOVID is within 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paxlovid （More than 5 days after the diagnosis of COVID-19）</arm_group_label>
    <description>According to the patient's medical records, the time from the diagnosis of COVID-19 to the prescription of PAXLOVID exceeds 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No paxlovid used</arm_group_label>
    <description>Patients have never used Paxlovid after being diagnosed with COVID-19, whether before or after hospitalization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paxlovid</intervention_name>
    <description>Patients treated with PAXLOVID within 5 days of being diagnosed with covid-19 will be included in this group. Patients treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.</description>
    <arm_group_label>Paxlovid（Within 5 days after the diagnosis of COVID-19）</arm_group_label>
    <other_name>paxlovid within initial 5 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No paxlovid</intervention_name>
    <description>Patients not treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.</description>
    <arm_group_label>No paxlovid used</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paxlovid</intervention_name>
    <description>Patients treated with PAXLOVID outside of the initial 5 days after being diagnosed with covid-19 will be included in this group.</description>
    <arm_group_label>Paxlovid （More than 5 days after the diagnosis of COVID-19）</arm_group_label>
    <other_name>Paxlovid outside of the initial 5 days</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Residual specimen, plasma, 1 ml. Each specimen will be uniquely identified to ensure that&#xD;
      patient privacy is not compromised.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will focus on COVID-19 infected patients who are admitted to the Beijing&#xD;
        Chaoyang Hospital, affiliated with Capital Medical University, from November 15th, 2022 to&#xD;
        March 30th, 2023.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of COVID-19 infection.&#xD;
&#xD;
          2. Presence of at least one high-risk factor, including age ≥60 years, diabetes,&#xD;
             hypertension, cardiovascular disease, stroke, chronic liver or kidney disease, cancer,&#xD;
             history of smoking or obesity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No specific exclusion criteria in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhuoling An, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chaohui Tong, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Zhang, PhD</last_name>
    <phone>+86 01085231464</phone>
    <email>jeffzhang1619@outlook.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 28, 2023</study_first_submitted>
  <study_first_submitted_qc>March 28, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 28, 2023</last_update_submitted>
  <last_update_submitted_qc>March 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Yi</investigator_full_name>
    <investigator_title>professer</investigator_title>
  </responsible_party>
  <keyword>Hospitalized</keyword>
  <keyword>paxlovid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

